Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Interest & Investment Income (2017 - 2025)

Autolus Therapeutics' Interest & Investment Income history spans 6 years, with the latest figure at $3.2 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 56.67% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $19.0 million, down 41.34%, while the annual FY2025 figure was $19.0 million, 41.34% down from the prior year.
  • Interest & Investment Income reached $3.2 million in Q4 2025 per AUTL's latest filing, down from $4.4 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $9.7 million in Q2 2024 to a low of $28000.0 in Q1 2022.
  • Average Interest & Investment Income over 4 years is $4.2 million, with a median of $3.5 million recorded in 2023.
  • Peak YoY movement for Interest & Investment Income: skyrocketed 12207.14% in 2023, then plummeted 56.67% in 2025.
  • A 4-year view of Interest & Investment Income shows it stood at $1.4 million in 2022, then skyrocketed by 111.08% to $3.0 million in 2023, then surged by 147.41% to $7.4 million in 2024, then tumbled by 56.67% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Interest & Investment Income are $3.2 million (Q4 2025), $4.4 million (Q3 2025), and $5.2 million (Q2 2025).